Abpro Holdings Inc. 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 15, 2026, there were5,896,048shares of common stock, par value $0.0001 per share, issued and outstanding. TABLE OF CONTENTS PART I - FINANCIAL INFORMATION ABPRO HOLDINGS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except for share and per share data) Commitments and Contingencies (Note 7) Stockholders’ deficit: Preferred stock, $0.0001 par value, 1,000,000 shares authorized; zero shares issued and outstanding--Common stock, $0.0001 par value; 110,000,000 shares authorized; 5,896,048 and 2,733,263 sharesissued and outstanding at March 31, 2026 and December 31, 2025, respectively1- The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. ABPRO HOLDINGS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Amounts in thousands, except share and per share data) 1. Organization and Description of the Business Organization Abpro Holdings, Inc. and its subsidiaries, (the “Company”) is a biotechnology company headquartered in Burlington, Massachusetts,dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threateningdiseases. The Company is focused on the development of novel antibodies using its proprietary discovery and engineering platforms, On November 13, 2024 (the “Closing Date”), Abpro Corporation (“Legacy Abpro”) completed the merger with Atlantic CoastalAcquisition Corp. II (“ACAB”) (the “Merger”). At the Closing Date, ACAB changed its name to “Abpro Holdings, Inc.” Reverse Stock Split On October 16, 2025, the Company filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate ofIncorporation of the Company (the “Certificate of Amendment”), which became effective on October 31, 2025 (the “Effective Time”),to effect a one-for-thirty (1:30) reverse stock split (the “Reverse Stock Split”), of the shares of the Company’s common stock, parvalue $0.0001per share. The Reverse Stock Split was approved by the Company’s stockholders at the 2025 annual meeting of the As a result of the Reverse Stock Split, every30shares of issued and outstanding common stock were automatically combinedintoone(1) issued and outstanding share of common stock, without any change in the par value per share. No fractional shares wereissued as a result of the Reverse Stock Split. Instead, stockholders who otherwise would have been entitled to receive fractional shares All of the Company’s historical share and per share information related to issued and outstanding common stock, restricted stock units,and options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but notlimited to, development by competitors of more advanced or effective therapies, dependence on key executives, protection of anddependence on proprietary technology, compliance with government regulations and ability to secure additional capital to fundoperations. Programs currently under development will require significant additional research and development efforts, including Going Concern The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubtabout its ability to continue as a going concern withinone yearafter the date that the condensed consolidated financial statements areissued. Through March 31, 2026, the Company has funded its operations mainly through equity and debt financings, including the As of March31, 2026 and December31, 2025, the Company had an accumulated deficit of $120,023 and $118,995, respectively. TheCompany’s net loss was $1,028 and $3,887 for the three months ended March31, 2026 and 2025, respectively. Substantially all of theCompany’s net losses resulted from costs incurred in connection with the Company’s research and development programs and from On April 2, 2025, the Company received